Thanks for always putting things in perspective Led.

Best wishes for 2016...but I am not as optimistic as you. I believe the RVX science will prove itself but until we see the trial results we won't see share price movement. (I always hope I am wrong).

This stock should be at least in the $6.00 Cdn range given that rvx-208 is in phase lll trial but with no NASDAQ it lacks credibility. That's OK because I'm a buyer, at least as far as my finances allow, so I can accumulate slowly.

The achievements since 2013 and long before have been remarkable. The $6.00 range means nothin to me. I'm in for the long haul and I do believe this drug will be a blockbuster. Of course that POV is "somewhat out there" but we are in phase lll and Hepalink has bought in.

So GLTA for 2016.

Cheers

Toinv